<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9853407</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">36688172</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">9853407</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.3389/fnagi.2022.1070535</article-id></all-ids><extracted-table><table-id>tab1</table-id><table-label>Table 1</table-label><table-caption>Baseline participant characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tab1"><label>Table 1</label><caption><p>Baseline participant characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" rowspan="1" colspan="1">rTMS group</th><th align="center" valign="middle" rowspan="1" colspan="1">Control group</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Total patients, no.</td><td align="char" valign="top" char="." rowspan="1" colspan="1">18</td><td align="char" valign="top" char="." rowspan="1" colspan="1">17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">84.8 (5.6)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">83.4 (4.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex, no. (%)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">10 (55)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">11 (64)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Completed college, no. (%)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">8 (44)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">9 (52)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Average time from AD diagnosis (y) (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">5.4</td><td align="char" valign="top" char="." rowspan="1" colspan="1">5.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medicated for AD (either ChEI or memantine or both) no. (%)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">18 (100%)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">17 (100%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MMSE, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">4.7 (3.9)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">3.4 (3.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MOCA, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">3.2 (4.3)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">1.8 (2.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NPI, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">22.4 (5.9)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">24.2 (6.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CIBIC-plus, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">27.2 (6.3)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">31.1 (5.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ADL, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">39.4 (25.7)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">42.9 (35.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SIB, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">30.7 (26.1)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">17.7 (22.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">r-TMS motor threshold, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">58.5</td><td align="char" valign="top" char="." rowspan="1" colspan="1">59.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APoE4/4 or ApoE4/3, no. (%)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">7 (38.9)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">7 (41.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">*Gray matter percentage, mean (SD)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">33.9 (2.6)</td><td align="char" valign="top" char="." rowspan="1" colspan="1">27.1 (11.9)</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; r-TMS, repetitive transcranial magnetic stimulation; NPI, neuropsychiatric inventory; MoCA, Montreal Cognitive Assessment; CIBIC, Clinician’s Interview-Based Impression of Change; SIB, severe impairment battery; ADL, activities of daily living. None of the differences were statistically significant. *Patients with fMRI data.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Baseline participant characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle">Characteristics</th><th align="center" valign="middle">rTMS group</th><th align="center" valign="middle">Control group</th></tr></thead><tbody><tr><td align="left" valign="top">Total patients, no.</td><td align="char" valign="top" char=".">18</td><td align="char" valign="top" char=".">17</td></tr><tr><td align="left" valign="top">Age, mean (SD)</td><td align="char" valign="top" char=".">84.8 (5.6)</td><td align="char" valign="top" char=".">83.4 (4.1)</td></tr><tr><td align="left" valign="top">Male sex, no. (%)</td><td align="char" valign="top" char=".">10 (55)</td><td align="char" valign="top" char=".">11 (64)</td></tr><tr><td align="left" valign="top">Completed college, no. (%)</td><td align="char" valign="top" char=".">8 (44)</td><td align="char" valign="top" char=".">9 (52)</td></tr><tr><td align="left" valign="top">Average time from AD diagnosis (y) (SD)</td><td align="char" valign="top" char=".">5.4</td><td align="char" valign="top" char=".">5.8</td></tr><tr><td align="left" valign="top">Medicated for AD (either ChEI or memantine or both) no. (%)</td><td align="char" valign="top" char=".">18 (100%)</td><td align="char" valign="top" char=".">17 (100%)</td></tr><tr><td align="left" valign="top">MMSE, mean (SD)</td><td align="char" valign="top" char=".">4.7 (3.9)</td><td align="char" valign="top" char=".">3.4 (3.7)</td></tr><tr><td align="left" valign="top">MOCA, mean (SD)</td><td align="char" valign="top" char=".">3.2 (4.3)</td><td align="char" valign="top" char=".">1.8 (2.7)</td></tr><tr><td align="left" valign="top">NPI, mean (SD)</td><td align="char" valign="top" char=".">22.4 (5.9)</td><td align="char" valign="top" char=".">24.2 (6.1)</td></tr><tr><td align="left" valign="top">CIBIC-plus, mean (SD)</td><td align="char" valign="top" char=".">27.2 (6.3)</td><td align="char" valign="top" char=".">31.1 (5.7)</td></tr><tr><td align="left" valign="top">ADL, mean (SD)</td><td align="char" valign="top" char=".">39.4 (25.7)</td><td align="char" valign="top" char=".">42.9 (35.8)</td></tr><tr><td align="left" valign="top">SIB, mean (SD)</td><td align="char" valign="top" char=".">30.7 (26.1)</td><td align="char" valign="top" char=".">17.7 (22.7)</td></tr><tr><td align="left" valign="top">r-TMS motor threshold, mean (SD)</td><td align="char" valign="top" char=".">58.5</td><td align="char" valign="top" char=".">59.1</td></tr><tr><td align="left" valign="top">APoE4/4 or ApoE4/3, no. (%)</td><td align="char" valign="top" char=".">7 (38.9)</td><td align="char" valign="top" char=".">7 (41.2)</td></tr><tr><td align="left" valign="top">*Gray matter percentage, mean (SD)</td><td align="char" valign="top" char=".">33.9 (2.6)</td><td align="char" valign="top" char=".">27.1 (11.9)</td></tr></tbody></table></div>AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; r-TMS, repetitive transcranial magnetic stimulation; NPI, neuropsychiatric inventory; MoCA, Montreal Cognitive Assessment; CIBIC, Clinician’s Interview-Based Impression of Change; SIB, severe impairment battery; ADL, activities of daily living. None of the differences were statistically significant. *Patients with fMRI data.</transformed-table></extracted-table></extracted-tables-set>